CytomX Therapeutics, Inc. (CTMX) operating margin

Operating margin · fiscal 2025
-29.3%

CytomX Therapeutics, Inc. (CTMX) had an operating margin of -29.3% in fiscal 2025 (the year ended December 31, 2025). That is 47.4 percentage points lower than the 18.1% of fiscal 2024. Figures as of 17 Nov 2026, 19:07 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Operating margin, fiscal 2025
-29.3%
Change on fiscal 2024
−47.4 pts
Highest on record
18.1%fiscal 2024
Lowest on record
-1684.2%fiscal 2013
Fiscal years on record
132013–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

CytomX Therapeutics, Inc. operating margin, in more detail

Across the 13 fiscal years on record (2013–2025), the highest was 18.1% in fiscal 2024 and the lowest -1684.2% in fiscal 2013. The fiscal 2025 figure is higher than in 83% of the 12 earlier fiscal years on record, whose median is -250.8%.

Net margin was -22.8% in fiscal 2025.

History · 13 fiscal years

Operating margin by fiscal year

  • Operating margin
  • Net margin

CytomX Therapeutics, Inc. operating margin, year by year

CytomX Therapeutics, Inc. (CTMX) operating margin by fiscal year
Fiscal yearOperating marginChangeYear endedNet margin
2025-29.3% 47.4 pts down-22.8%
202418.1% 24.5 pts up23.1%
2023-6.4% 184.2 pts up-0.6%
2022-190.6% 120.4 pts up-186.8%
2021-311.0% 193.3 pts down-310.5%
2020-117.7% 408.2 pts up-94.7%
2019-525.9% 395.0 pts down-493.7%
2018-130.9% 66.3 pts down-142.2%
2017-64.6% 399.3 pts up-60.2%
2016-463.9% 33.3 pts down-458.5%
2015-430.5% 155.7 pts up-458.7%
2014-586.3% 1098.0 pts up-597.0%
2013-1684.2%—-1705.3%

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Operating margin is operating income divided by revenue; gross margin does the same with gross profit, and net margin with net income.

How to read it

It shows how much of each unit of sales survives the cost of running the business — rising margins point to pricing power or scale, falling ones to pressure.

More on CTMX

CytomX Therapeutics, Inc., figure by figure

CytomX Therapeutics, Inc. (CTMX) overview: price, valuation and scorecard

CytomX Therapeutics, Inc. operating margin: questions and answers

What is CytomX Therapeutics, Inc.'s operating margin?

CytomX Therapeutics, Inc. (CTMX) had an operating margin of -29.3% in fiscal 2025 (the year ended December 31, 2025). That is 47.4 percentage points lower than the 18.1% of fiscal 2024.

Is CytomX Therapeutics, Inc.'s operating margin high or low compared with its own history?

The fiscal 2025 figure is higher than in 83% of the 12 earlier fiscal years on record, whose median is -250.8%.

What are the highest and lowest operating margin figures on record for CytomX Therapeutics, Inc.?

Across the 13 fiscal years on record (2013–2025), the highest was 18.1% in fiscal 2024 and the lowest -1684.2% in fiscal 2013.

What are CytomX Therapeutics, Inc.'s gross and net margins?

Net margin was -22.8% in fiscal 2025.

How is CytomX Therapeutics, Inc.'s operating margin calculated?

Operating margin is operating income divided by revenue; gross margin does the same with gross profit, and net margin with net income.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “CytomX Therapeutics, Inc. (CTMX) operating margin”, data as of 17 November 2026. https://funkfolio.com/stock/CTMX/operating-margin

Underlying data: the company's filings with the SEC and Yahoo Finance.